(232) Time to Therapeutic Decision in NSCLC: A Comparative Study of Liquid and Tissue Biopsies

Poster Abstract: Background/Rationale:
Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths worldwide, with a significant portion linked to cigarette smoking. The treatment landscape for NSCLC has undergone a considerable shift from cytotoxic therapies to advanced targeted agents and immunotherapies, emphasizing the crucial role of molecular testing in identifying effective treatments. While traditional tumor tissue biopsies have been the gold standard, their invasive nature and limited representation of the entire malignancy has led to the rise of liquid biopsies as a less invasive and more comprehensive diagnostic tool. Recent advancements indicate a shift towards liquid biopsies for detecting actionable biomarkers in NSCLC, especially in metastatic stages. At our institution newly diagnosed metastatic NSCLC patients undergo both tissue and liquid biopsies. The primary objective of our study is to demonstrate that liquid biopsies may be used to guide treatment decisions in newly diagnosed patients with advanced NSCLC. Additionally, this study aims to assess the progression-free survival (PFS) and overall survival (OS) of patients whose treatment regimen was initiated based on the results of a liquid biopsy. This approach potentially transforms the management of NSCLC, particularly in its advanced stages, by providing a less invasive, more rapid, and comprehensive diagnostic method.

Methods:
This study will be a retrospective chart review at Memorial Cancer Institute including adult patients with advanced NSCLC who underwent both tissue and liquid biopsies from July 1, 2015 to December 31, 2022. Analysis of the electronic medical records will encompass a range of variables: ethnicity, race, age, sex, diagnosis date, cancer stage, smoking history, histology, biopsy order and result dates, targetable mutations, the biopsy type guiding the final treatment decision, treatment initiated, disease progression/death dates. We will perform descriptive statistics (frequency, means, and standard deviations) for all demographic and baseline clinical outcomes.

Result: Results pending.

Conclusion/

Discussion: Conclusions/discussion pending.

References (must also be included in final poster): 1. Lung Cancer - Non-Small Cell - Statistics. Cancer.Net. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Published Mar 3, 2023. Accessed December 10, 2023.
2. Rijavec E, Coco S, Genova C, Rossi G, Longo L, Grossi F. Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers (Basel). 2019; 12(1):17. Published 2019 Dec 19.
3. Guibert N, Pradines A, Favre G, et al. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev 2020; 29: 190052.